- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Efzofitimod Fails to Reduce Steroid Use in Pulmonary Sarcoidosis but Improves Quality of Life: Study

USA: Efzofitimod was safe and well tolerated in patients with pulmonary sarcoidosis but did not significantly reduce corticosteroid doses compared with placebo at 48 weeks. However, structured steroid-tapering protocols enabled many patients to maintain substantially lower steroid doses for up to 32 weeks. Efzofitimod also improved patient-reported outcomes, including lung-related quality of life, general health, and fatigue.
- No significant steroid-sparing benefit: The placebo-adjusted change in daily corticosteroid dose was 0.02 mg in the 3 mg/kg efzofitimod group and −0.73 mg in the 5 mg/kg group, with neither difference reaching statistical significance.
- Sustained steroid reduction: Despite the absence of a significant treatment advantage, the structured tapering programme allowed many participants to maintain lower corticosteroid doses for up to 32 weeks.
- Improved patient-reported outcomes: Efzofitimod was associated with improvements in lung-related quality of life, general health and fatigue.
- Comparable serious adverse events: The proportion of patients experiencing serious treatment-emergent adverse events was similar across the three groups.
- Mostly mild adverse effects: Headache, sinusitis, wheezing, and increased aspartate aminotransferase levels were reported more frequently in the efzofitimod groups. Most adverse events were mild to moderate.
- Deaths during the trial: Two participants in the 3 mg/kg group died, one from respiratory failure and another from complications involving a pre-existing inguinal hernia. Neither death was considered related to the study treatment.
MSc. Biotechnology
Medha Baranwal holds a Bachelor’s degree in Biomedical Sciences from the University of Delhi and a Master’s degree in Biotechnology from Amity University. Since May 2018, she has been contributing to Medical Dialogues, writing and editing medical news articles that translate complex research into clear, accessible information for healthcare professionals.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

